---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence. Covers BOND-003 cohort C, BOND-003 cohort P, CORE-001, BOND-002, BOND, and V-0046. 271 evidence topics quoted from 53 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 BOND-003 Cohort C

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registry objective: complete response at any time in BCG-unresponsive CIS

> “To determine the Complete Response rate at any time in patients with BCG-unresponsive CIS with or without concomitant HG Ta/T1 papillary disease.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.1-2"></a>

###### Publication objective: response, safety, and tolerability

> “We evaluated the response and safety/tolerability of cretostimogene in patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.1-3"></a>

###### Trial-in-progress objective: confirmation of monotherapy activity

> “This single arm phase 3 study was launched to confirm the clinical activity of monotherapy CG0070 in patients with NMIBC unresponsive to BCG.”

Source: [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Centres and regions

> “BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.”
> “Sites were selected through a study team-led qualification process that evaluated feasibility, protocol alignment, operational capabilities, and regulatory readiness, as applicable.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.2-2"></a>

###### Countries named in the trial-in-progress report

> “The study is being conducted in the United States, Japan, South Korea, Australia, and Taiwan.”

Source: [Uchio et al. (2021)](https://cgoncology.com/wp-content/uploads/2025/11/2021_sitc_bond-003_poster-2.pdf)

<a id="topic-3.1.1.2-3"></a>

###### Proportion of participants enrolled in the United States

> “63.4% of patients in US”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.2-4"></a>

###### Enrollment period

> “Between Oct 9, 2020, and Aug 3, 2023”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.2-5"></a>

###### Enrollment status of Cohort C

> “Cohort C is closed to enrollment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.2-6"></a>

###### Latest efficacy data cutoff and median follow-up

> “As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1)”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “Efficacy data cutoff 23JUN2025”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.2-7"></a>

###### Next data release for Cohort C

> “Long-term Data Anticipated 2027”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Single-arm, open-label phase 3 design with separately analyzed cohorts

> “This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy.”
> “Cohort C and Cohort P will be analyzed and reported separately.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.3-2"></a>

###### Global trial in BCG-unresponsive CIS-containing and papillary disease

> “BOND-003 is a global, open-label, single-arm Phase 3 clinical trial designed to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients that have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta or T1 papillary tumors.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.3-3"></a>

###### Response assessment schedule and central confirmation

> “Response assessments include cystoscopy (biopsy as indicated) & cytology every 3 months for first 2 years and every 6 months starting Year 3; all responses are centrally confirmed”
> “All visible disease was resected prior to treatment”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Mandatory bladder mapping at 12 months

> “Patients undergo urine cytology and cystoscopy every 3 months for first 2 years, as well as mandatory bladder mapping at month 12.”
> “All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Design stated by the company to follow the 2018 FDA guidance

> “Trial designed to be compliant with 2018 FDA guidance”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria in the publication

> “We enrolled patients aged at least 18 years with Eastern Cooperative Oncology Group performance status of 0-2 and pathologically confirmed, high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without resected high-grade Ta or T1 disease.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.4-2"></a>

###### Definition of BCG-unresponsive disease

> “BCG-UR defined as persistent or recurrent CIS +/- Ta/T1 within 12 months of BCG therapy per FDA guidance”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.4-3"></a>

###### Registry inclusion criteria for Cohort C

> “Pathologically confirmed relapsed or persistent CIS (with or without HG Ta or HG T1 disease) within 12 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).”
> “Pathological confirmation of BCG unresponsive CIS within 8 weeks of study enrollment.”
> “CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.”
> “Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.4-4"></a>

###### Registry key exclusion criteria

> “Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer.”
> “Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.”
> “Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.”
> “Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of cretostimogene.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Dose and schedule in the publication

> “Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.5-2"></a>

###### Dose and schedule in the company annual report

> “The initial induction course of therapy is six weekly doses of cretostimogene containing 1x1012 VPs per milliliter.”
> “Patients who achieve a CR at month three receive maintenance treatments, involving three weekly cretostimogene doses administered at the same concentration every three months for the first 12 months and every six months for the next 24 months.”
> “Patients who do not achieve a CR after the first induction course may receive a second induction course of six weekly cretostimogene treatments at month 3, rather than the maintenance course involving three weekly treatments.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.5-3"></a>

###### Treatment courses

| Course | Schedule |
| --- | --- |
| Induction | “Weekly x 6” |
| Maintenance, year 1 | “Weekly x 3 Q3M for Year 1” |
| Maintenance, years 2 to 3 | “Weekly x 3 Q6M for Year 2-3” |
| Second induction | “Weekly x 6 for non-responders” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Registry arm description: DDM pretreatment and dosing weeks

> “Cretostimogene will be administered intravesically following a series of bladder washes with 5% DDM and normal saline.”
> “If the patient has disease recurrence at Week 13, they will receive another cycle of 6 weekly treatments.”
> “every 6 months starting at Weeks 73, 74, and 75 through Weeks 157, 158, and 159 until the tumor returns or study treatment is completed at Week 159.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.5-5"></a>

###### Instillation process used in Cohort C and in later studies

> “All studies beyond BOND-003 Cohort C use optimized instillation protocol”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

> “Prior to the administration of cretostimogene, patients undergo a saline wash and are then pretreated with n-Dodecyl-ß-D-maltoside (DDM) through IVE delivery.”
> “We have now streamlined this process and eliminated the saline and DDM wash steps.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Complete Response at Any Time as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint and secondary endpoints in the trial-in-progress report

> “The primary endpoint of the study is CR at anytime on study.”
> “Secondary endpoints will include CR at 12 m, duration of response, progression free survival, cystectomy free survival and safety.”

Source: [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint in the company annual report

> “The primary endpoint of the BOND-003 trial is CR at any time subsequent to induction.”
> “We designed this trial in light of the 2018 FDA guidance, and the revised draft guidance in August 2024, which defines BCG-unresponsive disease states and says that single-arm trials that assess CR rate as the primary endpoint, taking DOR into account, may be appropriate for full approval.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.6.1-3"></a>

###### Registry secondary outcomes for Cohort C

> “Cohort C: Duration of response (DOR)”
> “Median duration of response in patients with a CR or PR in subjects”
> “Cohort C:Complete Response rate at 12 months”
> “Cohort C and Cohort P : Cystectomy free survival”
> “Cohort C: Assess overall survival”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.6.1-4"></a>

###### Definition of complete response used in the trial

> “CR is defined as having a negative cystoscopy, a negative urine cytology, and a negative biopsy.”
> “In addition, all patients at 12-month timepoint undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR and detect potential occult disease in the bladder.”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Cystectomy-free survival: definition and rationale

> “Cystectomy-free survival defined as time from first dose to radical cystectomy or censoring”
> “Cystectomy-free survival is an important complementary endpoint that captures both disease control and bladder preservation for patients with high-risk BCG-unresponsive NMIBC”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### FDA 2018 guidance: complete response rate as the primary endpoint of a single-arm trial

> “a single-arm clinical trial with complete response rate and duration of response as the primary endpoint can provide primary evidence of effectiveness to support a marketing application.”
> “Currently, single-arm trials are appropriate for assessment of therapies for patients with BCG-unresponsive disease (CIS with or without resected papillary disease) because, currently, no effective medical therapies are available and the only alternative is radical cystectomy.”
> “The primary efficacy endpoint in single-arm trials of patients with BCG-unresponsive NMIBC should be the complete response rate in patients with CIS.”
> “The natural history of CIS is well understood, and the complete response rate is negligible in the absence of therapy.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### FDA 2018 guidance: confidence interval, duration of response, and assessment at 3 months

> “the lower bound of the 95 percent confidence interval around the observed response rate should rule out a clinically unimportant complete response rate.”
> “A high complete response rate is not meaningful if the response duration is short.”
> “However, the trial design should prespecify whether patients with CIS who do not achieve a complete response at their 3-month assessments should discontinue the investigational drug(s) because of the risk of progression.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.1.6.1-8"></a>

###### FDA 2024 draft guidance: complete response as an interpretable single-arm endpoint

> “making complete response (CR) an interpretable endpoint in the single arm setting.”
> “primary endpoint, supported by duration of response, can provide primary evidence of”
> “The primary efficacy endpoint in single-arm trials of patients with BCG-unresponsive NMIBC”
> “with CIS should be CR rate.”
> “A high CR rate is not meaningful if the response duration is short.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.1.6.1-9"></a>

###### International Bladder Cancer Group 2016: single-arm designs and clinically meaningful response rates

> “Single-arm designs may be relevant for the BCG-unresponsive population.”
> “Given the high risk of disease progression, a placebo-controlled arm is not ethical.”
> “For patients with BCG-unresponsive CIS, we recommend an initial CR rate of 50% at 6 months and durable response rates of 30% at 12 months and 25% at 18 months as clinically meaningful.”
> “In a recent FDA–AUA public workshop, some panel members felt that an initial CR rate of 40% to 50% at 6 months and a durable response rate of at least 30% for 18 to 24 months, with the lower bound of the 95% CI excluding 20%, could be clinically meaningful in the BCG-refractory CIS population.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-3.1.1.6.1-10"></a>

###### SITC and International Bladder Cancer Group 2023: complete response rate and duration in single-arm trials

> “For populations with CIS, CR rate and duration are clinically meaningful end points.”
> “Random assignment in this setting may be less acceptable to patients/providers, and single-arm trial designs have been permitted by the US Food and Drug Administration (FDA)”
> “Per FDA guidance, CR rate and duration should be benchmarked against historical agents or modern options (eg, valrubicin, pembrolizumab, gemcitabine and docetaxel, or nadofaragene firadenovec).”

Source: [Kamat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10713193/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the registry

> “Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C.”
> “Single treatment arm that enrolled 115 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment in the trial-in-progress report

> “110 patients with BCG-unresponsive CIS with or without concurrent Ta or T1 disease will be treated with intravesical (IVE) CG0070 at a dose of 1x1012 vp.”

Source: [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants enrolled, treated, and analyzed for efficacy

> “115 patients were enrolled in the study and 112 received cretostimogene”
> “complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.7.1-4"></a>

###### Efficacy-evaluable and safety populations

> “110 efficacy evaluable patients”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

> “Subjects in Safety Dataset”
> “N=112”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Efficacy and safety analysis populations

> “The primary endpoint was centrally confirmed complete response at any time in patients who received at least one dose of cretostimogene and completed the 3-month assessment; safety was assessed in those who received at least one dose of cretostimogene.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.7.2-2"></a>

###### Central confirmation, landmark and Kaplan-Meier analyses

> “Efficacy analysis centrally confirmed.”
> “Analysis based on both landmark CR rate assessed in clinical trial and CR by Kaplan-Meier estimate.”
> “Local : Central concordance: 97.1% of assessments”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Cystectomy-free survival analysis set

> “CFS calculated from first study treatment to cystectomy or censoring, whichever occurred first in the efficacy analysis set”

Source: [Steinberg et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/02/F13_BOND-003-Cohort-C-Cystectomy_Gary-Steinberg_Final.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Population labeled intention to treat for the 24-month landmark

> “High landmark CR at 24 mo in ITT population of 41.8% (46/110)”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Subgroup definitions for prior-therapy analyses

> “Second-Line: patients diagnosed with BCG-UR who received an additional therapy after adequate BCG.”
> “Prior Intervening Chemotherapy: adjuvant IVE chemotherapy before or after adequate BCG.”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Screening, enrollment, and treatment

> “Between Oct 9, 2020, and Aug 3, 2023, 165 patients were assessed for eligibility; 115 patients were enrolled in the study and 112 received cretostimogene.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.8.1-2"></a>

###### Treatment completion, discontinuation, and missed doses

> “97.3% received all protocol defined treatments”
> “No treatment related discontinuations”
> “Unrelated AE leading to treatment discontinuation was Hematuria (Grade 2).”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

> “no tx-related discontinuations; few missed (1.8%) or delayed (7.1%) doses”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.8.1-3"></a>

###### Radical cystectomy after recurrence or progression

> “18 patients underwent RC post-disease recurrence (n=12) or progression (n=6)”
> “1 additional patient had RC for UTUC”

Source: [Steinberg et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/02/F13_BOND-003-Cohort-C-Cystectomy_Gary-Steinberg_Final.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Sex and age in the publication

> “83 (74%) were male and 29 (26%) were female; median age was 74·0 years (IQR 68·5-79·5).”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.8.2-2"></a>

###### Demographics and disease characteristics, safety population

| Characteristic | n or value | % |
| --- | --- | --- |
| Male | “83” | “74.1” |
| Female | “29” | “25.9” |
| Age, mean (SD), years | “72.9 (9.19)” | |
| Age, median (range), years | “74.0 (43-90)” | |
| Age under 65 years | “19” | “17.0” |
| Age 65 to under 75 years | “43” | “38.4” |
| Age 75 years or older | “50” | “44.6” |
| Prior BCG instillations, median (range) | “12 (7 – 66)” | |
| CIS with high-grade Ta/T1 | “22” | “19.6” |
| CIS alone | “90” | “80.4” |
| At least 1 prior therapy other than BCG | “53” | “47.3” |
| Serial adjuvant chemotherapy | “34” | “30.4” |
| Systemic immunotherapy | “7” | “6.3” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Race, age group, and prior therapy summary

> “White (62%)”
> “> 65 years (83%)”
> “Prior chemotherapy (41%)”
> “Systemic Immunotherapy (6%)”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Prior BCG exposure and intervening therapy

> “These patients received a median of 12 prior BCG doses, some as high as 66. Prior intervening therapy also included intravesical chemotherapy (41.1%) and systemic immunotherapy (6.3%).”

Source: [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and)

<a id="topic-3.1.1.8.2-5"></a>

###### ECOG performance status, January 2025 data cutoff

| ECOG performance status | n | % |
| --- | --- | --- |
| 0 | “95” | “84.8” |
| 1 | “17” | “15.2” |

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-3.1.1.8.2-6"></a>

###### Second-line and prior intervening chemotherapy subgroups

> “23/110 (21%) patients: Second-Line BCG-UR”
> “34/110 (31%) patients Prior Intervening Chemotherapy, with”
> “>1 course of IVE gemcitabine (11/34; 32%)”
> “IVE gemcitabine-docetaxel (16/34; 47%)”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: complete response at any time, June 23, 2025 cutoff

> “As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1), complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “With a median follow-up time of 25.8 months, CR rate at any time is 75.5% (83/110) (95% CI 66.3-83.2%)”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### Company statement on the primary endpoint

> “BOND-003 Cohort C met its primary endpoint with statistical significance, exceeding historic and contemporary clinical benchmarks.”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

<a id="topic-3.1.1.8.3-3"></a>

###### Complete response at 12 and 24 months, June 23, 2025 cutoff

| Landmark | CR rate (95% CI) | Participants in CR | CR by Kaplan-Meier estimate (95% CI) |
| --- | --- | --- | --- |
| 12 months | “46.4% (36.9, 56.1)” | “51 out of 110 patients” | “50.7% (40.9, 59.8)” |
| 24 months | “41.8% (32.5, 51.6)” | “46 out of 110” | “42.4% (32.7, 51.7)” |

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### Complete response at 12 months: confidence interval reported in later presentations

> “46.4% (36.8, 56.1)”
> “Efficacy data cutoff as of 23JUN2025”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.3-5"></a>

###### Responders added at the 24-month assessment

> “All 9 ongoing CRs remained in response at the 24-month assessment, as well as 3 additional patients confirmed to be in CR at Month 24 after further follow-up and central pathologic adjudication.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.1.8.3-6"></a>

###### Duration of response, June 23, 2025 cutoff

> “Median DoR is 27.9 months and ongoing (95% CI 14.3-NE)”
> “Median follow-up of 25.8 months”
> “Estimated DOR Probability at 12 Months 64.2% (95% CI: 52.2-73.8)”
> “Estimated DOR Probability at 24 Months 60.1% (95% CI: 48.2-70.0)”
> “90% of patients in CR at 12 months, projected to remain in CR at 24 months”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

> “12- and 24-month duration of response (DOR) was 64.2% (95% CI 52.2–73.8) and 60.1% (95% CI 48.2–70.0), respectively.”
> “Median DOR is at least 27.9 months and is ongoing, with approximately 90% of patients in response at 12 months maintaining durable responses at 24 months, and one patient disease-free beyond 51 months.”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

<a id="topic-3.1.1.8.3-7"></a>

###### Duration of response rates attributed to the June 23, 2025 cutoff in September 2025

> “The study reported 75.5% CR at any time and 41.8% at 24 months with 46 confirmed CRs as of the cutoff date of June 23, 2025. The estimated 12- and 24-month duration of response (DOR) rates are 64.1% and 58.3%, respectively. Median DOR is 28 months and is ongoing.”

Source: [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and)

<a id="topic-3.1.1.8.3-8"></a>

###### Response after second induction

> “50.0% of patients reinduced with oncolytic immunotherapy converted to CR”
> “64.3% remain in durable response after conversion to CR”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

<a id="topic-3.1.1.8.3-9"></a>

###### Progression to muscle-invasive disease

> “96.4% (106/110) free from progression to ≥ T2 disease”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

> “96.6% of patients were free from progression to muscle invasive bladder cancer at 48 weeks and 96 weeks.”
> “we also observed a very low rate of progression to muscle-invasive bladder cancer, with only 3.4% of patients progressing during the study.”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

<a id="topic-3.1.1.8.3-10"></a>

###### Cystectomy-free survival

> “83.6% (92/110) did not undergo RC post recurrence or progression”
> “Median CFS not reached in the efficacy analysis set or any subgroups”
> “12-month: 89.2% (95% CI 81.3-93.9)”
> “24-month: 81.3% (95% CI 71.8-87.8)”
> “Based on Kaplan–Meier estimates”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.3-11"></a>

###### Radical cystectomy: timing and pathologic stage

| Measure | Value |
| --- | --- |
| Cystectomy any time after first recurrence, n (%) | “18 (16.4%)” |
| Cystectomy within the first year of recurrence, n (%) | “17 (15.5%)” |
| Weeks from recurrence or progression to cystectomy, median (Q1, Q3) | “20.0 (14.4, 26.7)” |
| Stage T0, n (%) | “1 (0.9)” |
| Stage CIS, n (%) | “9 (8.2)” |
| Stage HG Ta, n (%) | “1 (0.9)” |
| Stage T1, n (%) | “4 (3.6)” |
| Stage T2A, n (%) | “1 (0.9)” |
| Stage T2B, n (%) | “1 (0.9)” |
| Stage N2, n (%) | “1 (0.9)” |
| Participants with T0 or NMIBC at cystectomy | “15/18 (83.3%) were T0 or NMIBC” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.3-12"></a>

###### Cystectomy-free and progression-free rates at 24 months in a 2026 translational presentation

> “85% CFS and 97% PFS at 24 mo.”

Source: [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf)

<a id="topic-3.1.1.8.3-13"></a>

###### Complete response in second-line and prior intervening chemotherapy subgroups

> “23/110 (21%) patients: Second-Line BCG-UR”
> “CR rate at any time: 69.6% (16/23)”
> “34/110 (31%) patients Prior Intervening Chemotherapy, with”
> “CR rate at any time: 64.7% (22/34)”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="topic-3.1.1.8.3-14"></a>

###### Exploratory urinary tumor DNA analysis

> “Baseline utDNA available for 60 (53%) patients enrolled on BOND-003.”
> “Baseline utDNA did not predict the 24-mo. CR (p= 0.120).”
> “Week 13 urine was utDNA +ve in only 15 (31%) and –ve in 33 (69%) and predicted 24 mo. RFS.”
> “60% for MRD -ve and 30% for MRD +ve patients (p=0.019).”

Source: [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf)

<a id="topic-3.1.1.8.3-15"></a>

###### Complete response and duration of response at the September 30, 2024 cutoff

> “achieved a 74.5% complete response (CR) at any time in high-risk BCG-unresponsive NMIBC. As of the data cutoff of September 30, 2024, by Kaplan-Meier estimate, 63.5% and 56.6% of patients remained in response at 12 months or greater and at 24 months or greater, respectively, while the median DOR was not reached but exceeds 27 months.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.8.3-16"></a>

###### Complete response at 24 months and duration of response at the March 14, 2025 cutoff

> “33.7% (24.8, 43.8)”
> “34 out of 101 evaluable patients, pending 9 ongoing CRs that have yet to reach 24-month assessment”
> “Estimated DOR Probability at 12 Months 64.1% (95% CI: 52.4-73.7)”
> “Estimated DOR Probability at 24 Months 58.3% (95% CI: 46.3-68.5)”
> “Efficacy data cutoff as of 14MAR2025”

Source: [Tyson (2025a)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_C_Late-Breaking_Plenary.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-related adverse events in the publication

> “71 (63%) of 112 patients had at least one treatment-related adverse event, the most common being bladder spasm in 28 (25%) patients, pollakiuria in 25 (22%) patients, and micturition urgency in 23 (21%) patients; there were no grade 3 or 4 treatment-related adverse events and no treatment-related discontinuations or deaths.”
> “Two (2%) patients had serious treatment-related adverse events (one non-infective cystitis and one urinary bladder haemorrhage, both grade 2).”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.8.5-2"></a>

###### Treatment-related adverse events in more than 10% of participants, June 23, 2025 cutoff

| Preferred term (MedDRA v.26.1) | Any grade, n (%) | Grade 3 or higher, n (%) |
| --- | --- | --- |
| At least 1 treatment-related adverse event | “71 (63.4%)” | “0 (0)” |
| Bladder spasm | “28 (25.0%)” | “0 (0)” |
| Pollakiuria | “25 (22.3%)” | “0 (0)” |
| Urgency | “23 (20.5%)” | “0 (0)” |
| Dysuria | “21 (18.8%)” | “0 (0)” |
| Hematuria | “15 (13.4%)” | “0 (0)” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Severity, resolution, and serious treatment-related adverse events

> “Most AEs were Grade 1-2”
> “0% Grade ≥ 3 TRAEs or deaths”
> “Median time to TRAE resolution: 1 day”
> “1.8% (n=2) had serious treatment-related AEs (Grade 2)”
> “Treatment-related SAEs were noninfective cystitis (Grade 2) and clot retention (Grade 2).”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

> “The median time to resolution of related adverse events was 1 day (IQR 0–7).”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

> “Two patients (1.8%) had SAEs, including Grade 2 noninfective cystitis, and Grade 2 clot retention, both of which resolved.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: limitations of the BOND-003 Cohort C evidence

- Design: Cohort C is a single-arm, open-label trial with no concurrent control. The FDA 2024 draft guidance states that time-to-event endpoints are “uninterpretable in a single-arm trial” and that the lack of a comparator arm makes attributing adverse events difficult; cystectomy-free survival, progression-free survival, and duration of response therefore have no comparator in this trial. The FDA 2018 guidance states that patient and provider preferences “can confound the interpretation” of cystectomy delay, particularly in single-arm trials.
- Primary endpoint: complete response at any time includes participants with persistent disease who underwent repeat induction treatment, which a later trial of another agent did not permit. At the June 23, 2025 cutoff, 83 of 110 participants (75.5%) had a complete response at any time, while landmark complete response rates were 46.4% (51 of 110) at 12 months and 41.8% (46 of 110) at 24 months.
- Populations: 115 participants were enrolled, 112 were treated and form the safety population, and 110 who completed the 3-month assessment form the efficacy population. Eligibility required pathologically confirmed BCG-unresponsive CIS, ECOG performance status 0 to 2, and medical ineligibility for, or refusal of, radical cystectomy; prior systemic treatment for bladder cancer other than checkpoint inhibitors was excluded.
- Sources: the peer-reviewed report is available only as an abstract in the sources read, and most results beyond the abstract (12-month and 24-month landmark rates, duration of response, cystectomy outcomes, subgroups) come from company-sponsored congress presentations, press releases, and filings. The trial was funded by CG Oncology. The prespecified statistical threshold for the primary endpoint was not found in the public sources read; the company states that the trial “met its primary endpoint with statistical significance”.
- Figures that differ between documents for the same June 23, 2025 cutoff: duration of response at 12 and 24 months of 64.1% and 58.3% (September 2025 press release) against 64.2% and 60.1% (2026 press release and presentation); freedom from progression to muscle-invasive disease of 96.4% (106 of 110) against 96.6%; a lower 95% confidence bound for the 12-month landmark of 36.9% against 36.8%; 24-month cystectomy-free survival of 81.3% against 85% in a translational presentation; and the second serious treatment-related adverse event named as clot retention in a 2026 company presentation and the Form 10-K and as urinary bladder haemorrhage in the publication.
- Dose: the publication states a dose of “1 × 1012 viral particles per 0·8 mL”, and the company annual report states “1x1012 VPs per milliliter”.
- Applicability: Cohort C used a five-step instillation process that included saline and DDM washes; the company states that all later studies use a two-step process. No health-related quality-of-life or patient-reported outcome results were found.

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf); [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/); [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf); [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf); [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf); [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf); [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and); [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003); [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3); [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-3.1.1.9-2"></a>

###### FDA 2024 draft guidance: limits of single-arm trials

> “Time-to-event endpoints are uninterpretable in a single-arm trial.”
> “Lack of a comparator arm can make differentiating drug-related adverse events from”
> “those due to the underlying disease or other causes challenging.”
> “Standard of care intravesicular and systemic treatments exist for patients with BCG”
> “unresponsive NMIBC allowing for an RCT design.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.1.9-3"></a>

###### FDA 2018 guidance: cystectomy delay as an endpoint

> “Although delay in radical cystectomy is considered a direct patient benefit, the variations in patient and health care provider preferences can confound the interpretation of this endpoint in randomized trials and particularly in single-arm trials.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.1.9-4"></a>

###### Progression as an endpoint in BCG-unresponsive trials

> “Also, although progression is actually the clinically meaningful end point in this patient population, it is not practical to power these trials for progression.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-3.1.1.9-5"></a>

###### Company risk statements on topline data and regulatory sufficiency

> “Topline and preliminary data also remain subject to audit and verification procedures that may result, in the final data being materially different from the topline or preliminary data we previously published.”
> “we cannot be certain that our Phase 3 BOND-003 Cohort C trial for cretostimogene will be sufficient to support regulatory approval, even if we believe the results are sufficiently positive”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.9-6"></a>

###### Sponsor funding

> “Research funded by CG Oncology, Inc.”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

Additional sources: [Robesti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508430/)

<a id="heading-3.1.2"></a>

#### 3.1.2 BOND-003 Cohort P

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registry objective for Cohort P

> “To determine the high-grade EFS of cretostimogene in patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS”
> “To determine the all-cause High Grade Event Free Survival (HG-EFS) of cretostimogene in up to 75 patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.1-2"></a>

###### Company description of the cohort's purpose

> “We added an additional cohort (BOND-003 Cohort P) of up to 75 patients to evaluate the safety and efficacy of cretostimogene as a monotherapy in the treatment of patients with high-risk BCG-unresponsive NMIBC, Ta or T1 without CIS that have received adequate BCG therapy.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.2.1-3"></a>

###### Population evaluated as presented at congress

> “BOND-003 Cohort P evaluates cretostimogene in patients with HR BCG-UR with HG Ta/T1 (papillary-only)”
> “Additional bladder-sparing therapies are needed, especially for the BCG-Unresponsive HG Ta/T1 population”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Start of enrollment and site countries

> “First sites opened and patients enrolled March 2024”
> “35+ sites selected across North America and Japan”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="topic-3.1.2.2-2"></a>

###### Cohort initiation date stated in company filings

> “Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in BCG-unresponsive papillary only NMIBC.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-3.1.2.2-3"></a>

###### Countries enrolling in Cohort P per registry

> “Cohort P(Japan and United States Only) :Open to Enrollment”
> “Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.2-4"></a>

###### Registry dates for the whole BOND-003 study

| Field | Registry entry |
| --- | --- |
| Study start | “Study Start (Actual) 2020-10-27” |
| Primary completion | “Primary Completion (Estimated) 2030-06-16” |
| Study completion | “Study Completion (Estimated) 2031-12-24” |

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.2-5"></a>

###### Enrollment status reported in a 2025 trial-in-progress poster

> “Completed Enrollment”
> “35+ Sites Globally”

Source: [Tyson et al. (2025c)](https://cgoncology.com/wp-content/uploads/2025/11/SIU_TIPs_Bond-003-Cohort-P_Poster_Final-1.pdf)

<a id="topic-3.1.2.2-6"></a>

###### Geographic distribution of enrolled participants

> “96.4% of patients in US”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.2-7"></a>

###### Timing of the next data readout

> “BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Single-arm, open-label design with intravesical administration

> “Single-Arm, Open-Label, IVE Administration”
> “Primary Endpoint: HG Event Free Survival”
> “Mandatory biopsies at 12-month assessment”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="topic-3.1.2.3-2"></a>

###### Registry design details

> “Allocation : Non-Randomized Interventional Model : Single Group Assignment Masking : None (Open Label)”
> “Cohort C and Cohort P will be analyzed and reported separately.”
> “Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.3-3"></a>

###### Response assessment schedule

> “Response assessments include cystoscopy (biopsy as indicated) & cytology every 3 months for first 2 years and every 6 months starting Year 3”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Response assessment schedule as stated in November 2026

> “Response assessments include cystoscopy & cytology every 3 months for first 2 years and every 6 months starting Year 3, biopsy at 12 months”

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="topic-3.1.2.3-5"></a>

###### Regulatory role of the cohort after FDA feedback, November 2026

> “Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027”
> “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-3.1.2.3-6"></a>

###### Phase designation in the November 2026 investor presentation

> “Cohort P is a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.2.3-7"></a>

###### Phase designation in company filings and releases

> “Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease.”
> “Topline data from the Phase 3 BOND-003 Cohort P that was presented as a late-breaking abstract at the SUO 26th Annual Meeting in December 2025 showed that cretostimogene, as a single agent in patients with BCG-UR papillary-only NMIBC, demonstrated encouraging High-Grade Event-Free Survival (HG-EFS).”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Cohort P inclusion criteria

> “Have ECOG performance status of 0 to 2.”
> “Have pathologically confirmed (WHO grading system employed for tumor grading) (Compérat 2019) BCG-unresponsive HG Ta/T1 papillary disease without CIS.”
> “Pathologically confirmed recurrent HG Ta/T1 papillary disease without CIS within 6 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).”
> “Patients with HG Ta: Completion of qualifying BCG treatment (e.g., "5+2" minimum exposure) within 12 months of the initial qualifying dose of BCG”
> “Patients with HG T1: Patients may be eligible after the initial induction alone (5 of 6 doses of an induction course) as the qualifying BCG treatment.”
> “Completion (last dose) of qualifying BCG treatment within 12 months of study enrollment.”
> “Pathological confirmation of BCG-unresponsive HG Ta/T1 papillary disease without CIS within 14 days of study enrollment.”
> “Have all Ta and/or T1 disease resected, prior to study treatment (e.g., prior to Day 1 treatment).”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria shared by Cohorts C and P

> “Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer.”
> “Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.”
> “Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.”
> “Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of cretostimogene.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.4-3"></a>

###### Definition of BCG-unresponsive papillary disease as presented at congress

> “Enrolled patients with HG Ta/T1 without CIS”
> “BCG-Unresponsive defined as recurrent HG Ta/T1 within 6 months of last adequate BCG dose per FDA guidance”
> “HG T1 after single BCG induction course may be eligible”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dose, transduction-enhancing agent, and schedule per registry

> “In Cohort P, cretostimogene will be administered at a dose of 1 × 1012vp IVE following instillation of 5% DDM.”
> “Cretostimogene will be administered every week for 6 treatments on Weeks 1, 2, 3, 4, 5, and 6.”
> “If the patient has recurrence at Week 13 or any timepoint, the patient will receive a second induction of 6 weekly treatments (Weeks 13, 14, 15, 16, 17, and 18.).”
> “If the tumor has not returned they will receive 3 weekly treatments every 12 weeks (approximately 3 months) starting Weeks 13, 14, and 15 through Week 51 (approximately 12 months), and then every 6 months starting at Weeks 73, 74, and 75 (approximately 18 months) through Month 36.”
> “Transduction-enhancing agent.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.5-2"></a>

###### Induction, maintenance, and second induction courses

> “Induction Course: Weekly x 6”
> “3-yr Maintenance Course: Weekly x 3 Q3M for Year 1 Weekly x 3 Q6M for Year 2-3”
> “Second Induction: Weekly x 6 for non-responders”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using High-grade Event-free Survival as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint per registry and congress presentations

> “To determine the high-grade EFS of cretostimogene in patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

> “Primary Endpoint HG-EFS”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

> “The study’s primary endpoint is High-Grade Event-Free Survival (HG-EFS).”

Source: [CG Oncology SUO 2025 data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/new-cretostimogene-grenadenorepvec-data-highlight-its-potential)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary endpoint per the Form 10-K description of the cohort

> “The primary endpoint of this cohort is overall event-free survival, with secondary endpoints including safety, high-grade recurrence-free survival (RFS), low-grade RFS, PFS, cystectomy-free survival, and bladder cancer specific survival.”
> “The study’s primary endpoint is HG-EFS, and as of the September 1, 2025 data cut-off, in 51 efficacy evaluable patients, Kaplan-Meier estimates of HG-EFS at 3- 6- and 9-months are 95.7% (95% CI 83.8 – 98.9), 84.6% (95% CI 68.6 – 92.9%) and 80.4% (95% CI 62.3-90.4%), respectively.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.2.6.1-3"></a>

###### Definition of high-grade event-free survival used in the analysis

> “HG-EFS time from first study treatment (first re-induction dose) to high-grade recurrence, progression, death, or censoring.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.6.1-4"></a>

###### FDA recommendation for resected papillary disease

> “For patients without active disease (disease was resected at or before trial entry), FDA recommends a randomized, controlled trial design using a time-to-event endpoint such as recurrence-free survival.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

> “Time-to-event endpoints are uninterpretable in a single-arm trial.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.2.6.1-5"></a>

###### Sponsor's summary of FDA guidance on endpoints

> “Single-arm trials appropriate for BCG-UR NMIBC studies”
> “Time-to-event endpoint for patients with completely resected Ta/T1 disease”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="topic-3.1.2.6.1-6"></a>

###### International Bladder Cancer Group recommendations for papillary disease

> “Primary end points should include time to recurrence or recurrence-free survival (RFS) for fully resected papillary disease (because these patients have no evidence of disease at study entry)”
> “For patients with papillary disease that is BCG unresponsive, we consider recurrence-free rates of 30% at 12 months and 25% at 18 months as clinically meaningful.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

> “In scenarios where patients with CIS (with or without papillary disease) and papillary-only disease are evaluated separately, CR rate at 6 months and RFS, respectively, are appropriate primary end points.”
> “RFS in this setting includes death as an event and not a competing risk, distinct from low- and intermediate-risk NMIBC.”

Source: [Kamat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10713193/)

<a id="topic-3.1.2.6.1-7"></a>

###### Benchmarks cited by the sponsor for BCG-unresponsive papillary disease

> “Benchmarks reported from recent meta-analysis for BCG-UR HG Ta/T1 NMIBC”
> “73% at 3 mo”
> “58% at 6 mo”
> “48% at 12 mo”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.6.1-8"></a>

###### Secondary endpoints per registry

> “Cohort C and Cohort P: Assess high-grade reoccurrence free survival (RFS)”
> “Cohort C and Cohort P: Assess progression free survival (PFS )”
> “Cohort C and Cohort P : Cystectomy free survival”
> “Cohort C and Cohort P: Evaluate the safety of Cretostimogene”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.6.1-9"></a>

###### Secondary and additional endpoints per congress presentations

> “Secondary Endpoints RFS, PFS, CFS, CSS”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

> “HG RFS, LG RFS”
> “Bladder cancer-specific survival”
> “All-cause EFS”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

> “Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer.”
> “Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75.”
> “Enrollment (Estimated) 190”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants treated and evaluable at the September 2025 data cutoff

> “Cohort P (N=56):”
> “Patients in Safety Dataset N=56”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

> “At median follow-up 6 months, 51 patients are efficacy evaluable”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.7.1-3"></a>

###### Efficacy population stated in the November 2026 investor presentation

| Field | Cretostimogene, BOND-003 Cohort P |
| --- | --- |
| Efficacy population | “N=54” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants in the initial analysis, April 2025

> “Data from first 24 treated patients”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Safety and efficacy-evaluable analysis sets

> “Patients in Safety Dataset”
> “At median follow-up 6 months, 51 patients are efficacy evaluable”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Kaplan-Meier estimation and censoring

> “Kaplan-Meier Estimate for High Grade Event-Free Survival”
> “01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.”
> “Time from first treatment or re-induction (Months)”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Separate analysis of the two cohorts

> “Cohort C and Cohort P will be analyzed and reported separately.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Follow-up, re-induction, cystectomy, and treatment completion

> “Median follow-up: 6.0 months”
> “8 patients were re-induced at 3 months”
> “No patients underwent RC”
> “No treatment related discontinuations”
> “98.2% received all protocol defined treatments”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.1-2"></a>

###### Number re-induced as stated in November 2026

> “11 patients received re-induction”
> “98.2% of patients received protocol defined treatments”

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographics and disease characteristics of the safety dataset

| Characteristic | n | % |
| --- | --- | --- |
| Male | “44” | “78.6” |
| Female | “12” | “21.4” |
| Age, mean (SD), years | “71.6 (9.3)” | |
| Age, median (range), years | “74.0 (45-87)” | |
| Age < 65 years | “13” | “23.2” |
| Age ≥ 65 and < 75 years | “18” | “32.1” |
| Age ≥ 75 years | “25” | “44.6” |
| ECOG PS 0 | “48” | “85.7” |
| ECOG PS 1 | “8” | “14.3” |
| HG Ta at study entry | “33” | “58.9” |
| HG T1 at study entry | “23” | “41.1” |
| Prior BCG instillations, median (range) | “9.0 (5 – 21)” | |

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### Race and enrollment by country

> “White (87.5%)”
> “96.4% of patients in US”
> “High-Risk population enrolled, with 41.1% HG T1 at baseline”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.2-3"></a>

###### Tumor stage at study entry as stated in November 2026

| Characteristic | n | % |
| --- | --- | --- |
| HG Ta at study entry | “37” | “66.1” |
| HG T1 at study entry | “19” | “33.9” |

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### High-grade event-free survival at the September 2025 data cutoff

> “95.7% Est. 3-mo HG-EFS [95% CI: 83.8, 98.9]”
> “84.6% Est. 6-mo HG-EFS [95% CI: 68.6, 92.9]”
> “80.4% Est. 9-mo HG-EFS [95% CI: 62.3, 90.4]”
> “01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.3-2"></a>

###### Same estimates labeled as high-grade recurrence-free survival on the SUO 2025 slide

> “95.7% Est. 3-mo HG-RFS [95% CI: 83.8, 98.9]”
> “84.6% Est. 6-mo HG-RFS [95% CI: 68.6, 92.9]”
> “80.4% Est. 9-mo HG-RFS [95% CI: 62.3, 90.4]”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.3-3"></a>

###### High-grade event-free survival by tumor stage

| Time point | HG Ta | HG T1 |
| --- | --- | --- |
| 3 months | “92.8% (3 mo)” | “100% (3 mo)” |
| 6 months | “75.9% (6 mo)” | “100% (6 mo)” |
| 9 months | “75.9% (9 mo)” | “87.5% (9 mo)” |

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### Progression, cystectomy, and metastatic disease

> “No patients underwent RC”
> “No progression to MIBC”
> “1 pt progressed to metastatic urothelial carcinoma despite clinical complete response in the bladder.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.3-5"></a>

###### Company report of the topline results

> “As of the September 1, 2025, data cut-off, in 51 efficacy evaluable patients, Kaplan-Meier estimates of HG-EFS at 3- 6- and 9-months are 95.7% (95% CI 83.8 – 98.9), 84.6% (95% CI 68.6 – 92.9%) and 80.4% (95% CI 62.3-90.4%), respectively.”

Source: [CG Oncology SUO 2025 data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/new-cretostimogene-grenadenorepvec-data-highlight-its-potential)

<a id="topic-3.1.2.8.3-6"></a>

###### Twelve-month and 24-month estimates as of November 2026

| Time point | Cretostimogene, BOND-003 Cohort P |
| --- | --- |
| 3 months | “95.7 [95% CI: 83.8, 98.9]” |
| 6 months | “84.6 [95% CI: 68.6, 92.9]” |
| 9 months | “80.4 [95% CI: 62.3, 90.4]” |
| 12 months | “Not Yet Reached” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.2.8.3-7"></a>

###### Initial results in the first 24 treated participants, April 2025, superseded in December 2025

> “Data from first 24 treated patients”
> “Strong early responses with 90.5% HG-RFS (95% CI: 77.9-100%) at 3 and 9 Months”
> “90.5% Est. 6-mo HG-RFS [95% CI: 77.9, 100.0]”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Treatment-related adverse events reported in more than 10% of participants

| Preferred term | Any grade, n (%) | Grade ≥ 3, n (%) |
| --- | --- | --- |
| Participants with ≥1 TRAE | “40 (71.4%)” | “0 (0)” |
| Bladder spasm | “26 (46.4%)” | “0 (0)” |
| Dysuria | “22 (39.3%)” | “0 (0)” |
| Pollakiuria | “14 (25.0%)” | “0 (0)” |
| Urgency | “11 (19.6%)” | “0 (0)” |

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### Severity, serious events, deaths, and dosing interruptions

> “Safety data cutoff as of 01SEP2025”
> “Most AEs were Grade 1-2”
> “0% Grade ≥ 3 TRAEs, Serious TRAE, deaths”
> “No dose delays, missed doses due to TRAEs”
> “No treatment related discontinuations”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.5-3"></a>

###### Safety summary in the Form 10-K

> “A favorable safety and tolerability profile was observed as of the September 1, 2025 safety data cutoff, with no Grade 3 or greater TRAEs and no deaths reported.”
> “The most common TRAEs (≥10%) were bladder spasms, dysuria, pollakiuria, and hematuria.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.2.8.5-4"></a>

###### Safety summary as stated in November 2026

> “No grade ≥ 3 TRAEs, serious TRAE, deaths”
> “No dose delays, missed doses, or discontinuations due to TRAEs”

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: limitations of the Cohort P evidence

- Design: Cohort P is a single-arm, open-label cohort with no concurrent control. FDA guidance recommends a randomized, controlled design with a time-to-event endpoint for disease resected at or before trial entry and states that “Time-to-event endpoints are uninterpretable in a single-arm trial”.
- Maturity: all reported efficacy results come from one data cutoff (September 1, 2025), at a median follow-up of 6.0 months. Of 56 participants in the safety dataset, 51 were efficacy evaluable, and 5 censored participants were pending efficacy assessment. Twelve-month estimates were “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
- Publication status: the results have been reported in congress presentations, company filings, and press releases. No peer-reviewed publication of Cohort P was identified.
- Primary endpoint wording: the registry states a high-grade event-free survival endpoint (“all-cause High Grade Event Free Survival (HG-EFS)”), while one passage of the Form 10-K states that the primary endpoint “is overall event-free survival” and another passage of the same filing states that it “is HG-EFS”. The SUO 2025 slide labels the same three Kaplan-Meier estimates HG-RFS.
- Sample size: the registry target is 75 participants, while 56 participants were in the safety dataset at the data cutoff, and a 2025 trial-in-progress poster reported “Completed Enrollment”. The registry still lists Cohort P as open to enrollment. The 2026 investor presentation gives an efficacy population of “N=54”, against 51 efficacy-evaluable participants in the congress presentations.
- Inconsistent figures for the same data cutoff: the SUO 2025 podium reports 33 HG Ta (58.9%) and 23 HG T1 (41.1%) participants and one 2026 poster reports 8 re-induced participants; another 2026 poster reports 37 HG Ta (66.1%) and 19 HG T1 (33.9%) participants and 11 re-induced participants. The Form 10-K lists hematuria among the most common TRAEs, which the SUO 2025 table of TRAEs does not include.
- Regulatory role: company documents describe the cohort as “Phase 3”, as “an exploratory study”, and as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the BLA would be broadened to include high-grade papillary-only disease.
- Generalizability: 96.4% of participants were enrolled in the US, 87.5% were White, and 85.7% had ECOG performance status 0. No health-related quality of life or patient-reported outcome results were identified.
- Comparisons: sponsor materials set Cohort P estimates beside results of other agents from separate trials; the investor presentation states that these data are not based on head-to-head or comparator studies.

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf); [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf); [Tyson et al. (2025c)](https://cgoncology.com/wp-content/uploads/2025/11/SIU_TIPs_Bond-003-Cohort-P_Poster_Final-1.pdf); [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf); [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf); [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3); [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and); [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-3.1.2.9-2"></a>

###### Interim data maturity and censoring

> “Median follow-up: 6.0 months”
> “01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.9-3"></a>

###### Single-arm design and interpretability of time-to-event endpoints

> “Time-to-event endpoints are uninterpretable in a single-arm trial.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.2.9-4"></a>

###### Cross-trial comparisons in sponsor materials

> “Note: These data are not based on head-to-head or comparator studies.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="heading-3.1.3"></a>

#### 3.1.3 CORE-001

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Study purpose in the ClinicalTrials.gov record

> “To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.1-2"></a>

###### Study question in the published final results

> “In this phase 2 study, we assessed the potential synergistic efficacy between intravesical cretostimogene and systemic pembrolizumab in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS).”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.1-3"></a>

###### Primary and secondary objectives in the clinical study protocol

> “Evaluate the complete response rate at 12 months of CG0070 combined with pembrolizumab in patients with BCG unresponsive carcinoma in situ (CIS) with or without concomitant high-grade Ta (TaHG) or T1 papillary disease”
> “Evaluate the safety of CG0070 combined with pembrolizumab”
> “Determine the complete response rate at any time on study”
> “Assess the duration of response (DoR)”
> “Assess progression free survival (PFS)”
> “Determine cystectomy free survival”
> “Assess the rate of delayed response beyond 3 months following treatment”
> “Evaluate the differential response in patients with persistent and relapsed disease”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.1-4"></a>

###### Expected benefit of the combination in the clinical study protocol

> “Both agents have demonstrated activity when used as single agents in NMIBC.”
> “It is anticipated that the combination may result in greater activity than either agent alone based on an augmented immune response to CG0070 in the presence of pembrolizumab.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates, enrollment, and sites in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2020-12-08” |
| Primary completion (actual) | “2023-03-07” |
| Study completion (actual) | “2024-05-28” |
| Enrollment (actual) | “35” |
| Sites | “This study has 19 locations” |

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.2-2"></a>

###### Enrollment by country in the published final results

| Country | Participants, n (%) |
| --- | --- |
| USA | “30 (85.7)” |
| Korea | “5 (14.3)” |

Source: [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1)

<a id="topic-3.1.3.2-3"></a>

###### Planned accrual period and end of long-term follow-up in the clinical study protocol

> “Study accrual is expected to occur over a period of 24 months, therefore the time from the start of accrual to the last patient visit is estimated at 48 months.”
> “Under Protocol Amendment 7, no additional Long-Term Efficacy Follow-Up assessments will be completed, and no additional Long-Term Efficacy Follow-Up data will be collected.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.2-4"></a>

###### Data cutoffs for the final results

> “As of the data cutoff on February 5, 2024, the CR rate in the intention-to-treat (ITT) population at 12-months and any time, was 57% (20/35) [95% confidence interval (CI), 40-73%] and 83% (29/35) (95% CI, 70-95%), respectively.”
> “As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).”

Source: [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)

<a id="topic-3.1.3.2-5"></a>

###### Publication and congress presentation of the final results

> “The most recent data cut as of May 17, 2024, was also featured as a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.”

Source: [CG Oncology CORE-001 Nature Medicine publication press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-nature-medicine-publication-final-results)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Single-arm, open-label design in the ClinicalTrials.gov record

| Design characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Collaborator | “Merck Sharp & Dohme LLC” |

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.3-2"></a>

###### Design overview and safety lead-in cohort in the clinical study protocol

> “This is a Phase 2, open-label, trial designed to evaluate CG0070 and DDM in combination with pembrolizumab in patients with NMIBC who have failed prior BCG therapy.”
> “Up to 35 patients with CIS with or without concomitant TaHG or T1 papillary disease will be enrolled.”
> “For the purposes of establishing the safety of CG0070 combined with pembrolizumab, the initial 10 patients will be considered a ‘lead in cohort’.”
> “Thereafter, an additional 25 patients will be enrolled.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.3-3"></a>

###### Disease assessments and central review in the clinical study protocol

> “While on study treatment, all patients will undergo urine cytology and cystoscopy with directed biopsy of any suspicious lesions every 12 weeks for up to 2 years.”
> “In all patients, an upper urinary tract evaluation utilizing CT urogram or MRU will be performed every 48 weeks on study.”
> “Central review of safety laboratory, cytology, pathology, and radiographic studies will be completed for all patients.”
> “During Long-Term Efficacy Follow-Up, response assessments will be based on local review.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.3-4"></a>

###### Trial design and Merck supply agreement in the annual report

> “CORE-001 was a Phase 2 single-arm, open-label clinical trial of cretostimogene administered in up to 35 patients with high-risk BCG-unresponsive NMIBC that have CIS-containing tumors, in combination with pembrolizumab, following disease resection.”
> “We entered into a clinical trial collaboration and supply agreement with Merck providing at no-cost supply of pembrolizumab for use in CORE-001 (which agreement also provides for the joint ownership of clinical trial data but has no additional financial obligations and terminates upon conclusion of the trial).”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion criteria in the clinical study protocol

> “Be ≥18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.”
> “Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.”
> “Relapsed or persistent CIS (with or without TaHG or T1 disease) within 12 months of the completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, TaHG, T1, or a combination of these HGUC pathologies).”
> “Pathological confirmation of BCG unresponsive CIS within 10 weeks of study enrollment.”
> “CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.”
> “Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).”
> “At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 3 doses of maintenance therapy, OR”
> “At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 6 doses of a second induction course.”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.4-2"></a>

###### Key exclusion criteria in the clinical study protocol

> “Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)”
> “Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer”
> “Has had prior treatment with any human adenovirus serotype 5 based therapy (e.g., Ad-interferon or Instiladrin)”
> “Has significant immunodeficiency due to underlying illness (e.g., known HIV/AIDS)”
> “Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).”
> “Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis”
> “Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of CG0070.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.4-3"></a>

###### Definition of BCG-unresponsive disease and the 15-month assessment window in the ClinicalTrials.gov record

> “Unresponsive to prior BCG therapy (Lerner 2015) defined as persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the sub- epithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.”
> “An assessment within 15 months can also qualify when no assessment was performed within 12 months after completion of adequate BCG therapy.”
> “Adequate BCG is defined as at least 5 treatments with induction BCG followed by at least 2 BCG treatments as reinduction or maintenance”
> “Prior therapy with or intolerant to prior checkpoint inhibitor therapy”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.4-4"></a>

###### FDA guidance as the basis of the BCG-unresponsive definition in the clinical study protocol

> “The definition of BCG unresponsive disease will follow the standard U.S. Food and Drug Administration (FDA) guidance document”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment schedule in the published final results

> “Thirty-five patients were treated with intravesical cretostimogene with systemic pembrolizumab.”
> “Induction cretostimogene was administered weekly for 6 weeks followed by three weekly maintenance infusions at months 3, 6, 9, 12 and 18 in patients maintaining complete response (CR).”
> “Patients with persistent CIS/high-grade Ta at the 3-month assessment were eligible for re-induction.”
> “Pembrolizumab was administered for up to 24 months.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.5-2"></a>

###### Cretostimogene dose and schedule in the clinical study protocol

> “CG0070 will be administered at a dose of 1 × 1012 viral particles (vp) intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline.”
> “If the patient has persistent CIS, TaHG, or CIS with TaHG at Week 13, the patient will receive another cycle of 6 weekly treatments on Weeks 13, 14, 15, 16, 17, and 18.”
> “If there is no disease present at Week 13 (e.g., the patient has a complete response), the patient will receive 3 weekly treatments on Weeks 13, 14, and 15.”
> “Beginning at Week 25, all patients will receive 3 weekly treatment cycles every 12 weeks through Week 51 then a last treatment cycle of CG0070 at Weeks 73, 74, and 75 until either the patient discontinues from the study treatment or after 24 months.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.5-3"></a>

###### Bladder wash and instillation procedure with DDM in the clinical study protocol

> “Initial bladder wash with 100 mL normal saline”
> “Second bladder wash with 75 mL 0.1% DDM”
> “Instillation of 100 mL 0.1% DDM for 15 minutes (±5 minutes)”
> “Third bladder wash with 100 mL of normal saline”
> “Instillation of 100 mL CG0070 in normal saline (within 30 minutes [±5 minutes] of initial saline wash) with 1 hour dwell time (±5 minutes) from time of complete instillation”
> “Patients will be monitored for at least 1 hour following IVE treatment to observe safety and collect protocol specified research samples”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.5-4"></a>

###### Pembrolizumab dose and transition from every-3-week dosing in the clinical study protocol

> “Pembrolizumab 400 mg IV will be given concurrently starting on Day 1 and continue every 6 weeks for a completion of 18 administrations (approximately 2 years)”
> “As applicable, for patients started on 200 mg IV every 3 weeks (under the initial trial design), transition to 400 mg IV every 6 weeks will commence at Weeks 7, 13, 19, 25 etc. (e.g., at 6-week intervals from initiation of pembrolizumab).”
> “A 400 mg Q6W dosing regimen of pembrolizumab is expected to have a similar benefit-risk profile as 200 mg Q3W, in all treatment settings in which 200 mg Q3W pembrolizumab is currently appropriate (Lala 2020).”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.5-5"></a>

###### Treatment arm in the ClinicalTrials.gov record

> “CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline.”
> “Beginning at Week 25, patients will receive weekly x 3 treatments every 3 months through Week 49 then every 24 weeks thereafter.”
> “Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 6 weeks for up to 2 years.”
> “Transduction-enhancing agent.”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.5-6"></a>

###### Dose concentration and dosing schedule in the annual report

> “Patients that demonstrate a CR after an initial six-week induction phase of weekly cretostimogene administrations, dosed at a concentration of 1x1012 VP per milliliter, who also receive two, 400 mg doses of pembrolizumab over three months, are given a maintenance course of three weekly doses of cretostimogene at an equivalent VP concentration, along with two doses of pembrolizumab for three months.”
> “The dosing schedule of intravesical cretostimogene in CORE-001 is similar to BOND-003, while pembrolizumab is administered pursuant to its approved dosing schedule.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Complete Response at 12 Months as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary and secondary endpoints in the published final results

> “The primary endpoint was CR at 12 months as assessed by cystoscopy, urine cytology, cross-sectional imaging and mandatory bladder mapping biopsies.”
> “Secondary endpoints included CR at any time, duration of response, progression-free survival and safety.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.6.1-2"></a>

###### Primary outcome in the ClinicalTrials.gov record

> “Complete response rate in patients”
> “Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.6.1-3"></a>

###### Mandatory bladder mapping at 12 months in the clinical study protocol

> “At Week 49, in addition to the assessment of urine cytology, cystoscopy, directed biopsy, and CTU urogram/MRU, mandatory bladder mapping (random biopsy of the trigone, bladder dome, right, left, and posterior bladder walls and a prostatic urethra biopsy [prostatic urethra biopsy required in males with prior documented involvement]) will be conducted to assess disease status and confirm complete response.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-4"></a>

###### Definition of complete response in the clinical study protocol

> “Notably, low-grade disease will not be regarded as non-response for the purposes of assessing complete response in this study.”
> “Negative cystoscopy, negative urine cytology (NOTE: atypical cytology will be regarded as negative), and negative biopsy as appropriate (e.g., biopsy of areas on cystoscopy suspicious for malignancy at 12-week assessments)”
> “Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology (or positive cytology if found in conjunction with low-grade NMIBC)”
> “Positive (malignant or suspicious) cytology in the absence of an identifiable source”
> “Urothelial carcinoma of the upper tract, prostatic urethra, or other extra-vesicular disease will count as non-response.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-5"></a>

###### Historical 12-month complete response rates cited as the basis for the null hypothesis in the clinical study protocol

> “For the purpose of study design, a complete response rate at 12 months of 19% (H0) for the experimental regimen in this setting will not be viewed as compelling for further study while a complete response rate of 36% (Ha) or more will be considered of interest for further investigation.”
> “The overall response rate at any time was 41% and duration of response (DoR) was 16.2 months, while the response rate at 12 months was estimated at ~20%.”
> “The complete response rate was 51%, the median duration of response was 9.7 months, and 46% of responding patients remained in complete response for at least one year (Adstiladrin [nadofaragene firadenovec-vncg] USPI 2022).”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-6"></a>

###### Complete response rate with duration of response as the single-arm endpoint in FDA guidance

> “The primary efficacy endpoint in single-arm trials of patients with BCG-unresponsive NMIBC should be the complete response rate in patients with CIS.”
> “Sponsors should consider the complete response rate in the context of the duration of response.”
> “A high complete response rate is not meaningful if the response duration is short.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.3.6.1-7"></a>

###### Clinically meaningful durable response rate at 12 months in International Bladder Cancer Group recommendations

> “BCG-unresponsive CIS: an initial CR rate of 50% at 6 months and a durable response rate of 30% at 12 months and 25% at 18 months would be clinically meaningful”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-3.1.3.6.1-8"></a>

###### Secondary endpoints in the clinical study protocol

> “Safety of CG0070 and pembrolizumab (AEs) including incidence, severity and relationship using CTCAE version 5.0”
> “Complete response rate at any time”
> “Duration of response”
> “Cystectomy free survival”
> “Progression free survival”
> “Overall survival”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-9"></a>

###### Exploratory endpoints including viral shedding in the clinical study protocol

> “Evaluate anti-tumor and anti-viral immune response including assessment of immune response in the peripheral blood, urine, and tumor microenvironment”
> “Evaluate tumor PD-L1, E2F transcription factor, and CAR expression”
> “Evaluate urine, blood, saliva, and tissue levels of CG0070”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Sample size calculation in the clinical study protocol

> “The statistical design is a single-stage design using a standard 1-sided normal statistical test of a single binomial proportion with no interim analysis.”
> “The primary analysis will test H0: π ≤0.19 versus Ha: π >0.19 using a single proportion asymptotic normal test statistic, at alpha 1-sided 0.10.”
> “With the specified sample size there will be approximately 81% power for this test if the true population proportion is 36%.”
> “Using these operating characteristics for study design, a total of 30 evaluable patients will be accrued.”
> “If ≥9/30 have a complete response, H0 will be rejected and activity at least at 36% response rate concluded.”
> “Finally, an additional 5 patients may be added to account for potential non-evaluable patients (e.g., lost to follow-up or withdrawal of consent prior to the first response assessment) resulting in a total patient number of 35.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.1-2"></a>

###### Target and actual enrollment in the ClinicalTrials.gov record

> “The target population of 37 subjects with CIS with or without concomitant high-grade Ta or T1 papillary disease will be enrolled.”
> “Enrollment (Actual) 35”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.7.1-3"></a>

###### Participants treated and analyzed in the published final results

> “Thirty-five patients were treated with intravesical cretostimogene with systemic pembrolizumab.”
> “The CR rate in the intention-to-treat population at 12 months was 57.1% (20 out of 35, 95% confidence interval (CI) 40.7–73.5%), meeting the primary endpoint.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Analysis populations in the clinical study protocol

> “Enrolled: All patients who have provided informed consent, met all inclusion criteria, and are enrolled in the study”
> “All Treated: All patients who receive at least one dose of CG0070.”
> “Efficacy-Evaluable: All patients who have received at least one dose of CG0070, met the definition of BCG-unresponsive NMIBC at baseline, and completed protocol-specified efficacy assessments post-baseline”
> “Efficacy will be presented as the percentage of patients with complete response within the Enrolled and Efficacy-Evaluable analysis populations.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Handling of participants without a 12-month assessment and time-to-event methods in the clinical study protocol

> “Patients who complete the initial study specified response assessment but fail to reach the 12-month evaluation for response will be considered non-complete responders.”
> “Time based endpoints (e.g., disease free survival, duration of response, time to cystectomy, time to progression, disease-specific survival, overall survival) will be displayed using Kaplan Meier statistics.”
> “Analyses performed for this study will utilize descriptive statistics.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Safety analysis methods in the clinical study protocol

> “The incidence of all AEs will be tabulated and classified by system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA).”
> “For incidence reporting, if a patient reported more than one AE that was coded to the same system organ class or preferred term, the patient will be counted only once at the highest observed grade for that specific system organ class or preferred term.”
> “Treatment emergent AEs will be captured from Day 1 through 30 days after the last treatment with CG0070 or pembrolizumab; however, SAEs resulting from a screening procedure will also be captured.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Evaluable-patient denominators in the annual report

> “Moreover, administration of cretostimogene has also resulted in durable responses, with 81.8% (n=27/33) of the evaluable patients maintaining a CR at six months and 68.0% (n=17/25) of evaluable patients maintaining a CR at 12 months, each as of the cutoff date.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Reasons for discontinuation without disease recurrence

| Participant ID | Dropout study timepoint | Primary reason |
| --- | --- | --- |
| 1113002 | “Month 3” | “Patient discontinued the study prior to completion of all the required protocol evaluations at 3-months (with no evidence of disease recurrence)” |
| 1101006 | “Month 6” | “Complete Response at Month 3; death of non-bladder related reasons (with no evidence of treatment toxicity or disease recurrence)” |
| 1117001 | “Month 9” | “Complete Response at Month 6; withdrew from study due to comorbidities unrelated to study treatment (with no evidence of disease recurrence)” |
| 1110004 | “Month 9” | “Complete Response at Month 6; withdrew consent from further treatment (with no evidence of disease recurrence)” |
| 1204001 | “Month 12” | “Complete Response at Month 9; patient withdrew consent from further treatment and efficacy evaluations (with no evidence of disease recurrence)” |
| 1206001 | “Month 15” | “Complete Response through Month 12; patient withdrew consent from further treatment and efficacy evaluations (with no evidence of disease recurrence)” |

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.8.1-2"></a>

###### Reasons for screen failure

| Participant ID | Entry criterion not met | Details |
| --- | --- | --- |
| 1105001 | “EXCLUSION 15” | “Has a known additional malignancy that is progressing or has required active treatment within the past 3 years” |
| 1116001 | “INCLUSION 10” | “Patients must be willing to comply with study mandated cystoscopies, urine cytology, urograms, biopsies, and other procedures” |
| 1118001 | “INCLUSION 4” | “Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment” |
| 1101005 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1115004 | “INCLUSION 5” | “Received prior adequate BCG therapy as defined per protocol” |
| 1102001 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1117002 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1101009 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1101012 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline characteristics in the published final results

| Characteristic | n = 35 |
| --- | --- |
| Age, median | “72” |
| Age, range | “57–90” |
| Sex, male | “33 (94.3)” |
| Sex, female | “2 (5.7)” |
| ECOG 0 | “25 (71.4)” |
| ECOG 1 | “9 (25.7)” |
| ECOG 2 | “1 (2.9)” |
| Race, White | “27 (77.1)” |
| Race, Black/African American | “2 (5.7)” |
| Race, Asian | “5 (14.3)” |
| Race, unknown | “1 (2.9)” |
| Stage, CIS | “27 (77.1)” |
| Stage, CIS + high-grade Ta | “4 (11.4)” |
| Stage, CIS + high-grade T1 | “4 (11.4)” |
| Prior BCG courses, 2 | “18 (51.4)” |
| Prior BCG courses, 3 | “8 (22.9)” |
| Prior BCG courses, 4 | “2 (5.7)” |
| Prior BCG courses, 5 | “4 (11.4)” |
| Prior BCG courses, ≥6 | “3 (8.6)” |

Source: [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1)

<a id="topic-3.1.3.8.2-2"></a>

###### Prior BCG instillations and persistent or recurrent disease in the interim presentation

| Characteristic | Quoted value |
| --- | --- |
| Number of prior BCG instillations, median (range) | “12 (9 - 30)” |
| Persistent high-risk NMIBC, n | “21” |
| Persistent high-risk NMIBC, % | “60” |
| Recurrent high-risk NMIBC, n | “14” |
| Recurrent high-risk NMIBC, % | “40” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.3.8.2-3"></a>

###### Participants enrolled at U.S. sites in a pooled demographic analysis

> “Retrospective analysis of HR BCG-UR NMIBC patients enrolled from BOND-003 (n=71) and CORE-001 (n=30) across U.S. based sites”
> “Enrollment characteristics across two cretostimogene studies with HR BCG-UR NMIBC demonstrate a generalizable racial, ethnic, and gender distribution”

Source: [Lotan et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SCSAUA_Lotan_007_Clinical-Trials-Demographics-1-1.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Complete response at 12 months, 3 months, and 24 months in the published final results

> “The CR rate in the intention-to-treat population at 12 months was 57.1% (20 out of 35, 95% confidence interval (CI) 40.7–73.5%), meeting the primary endpoint.”
> “A total of 29 out of 35 patients (82.9%, 95% CI 70.4–95.3%) derived a CR at 3 months.”
> “With a median follow-up of 26.5 months, the median duration of response has not been reached (95% CI 15.7 to not reached).”
> “The CR rate at 24 months was 51.4% (18 out of 35) (95% CI 34.9–68.0%).”
> “No patient progressed to muscle-invasive bladder cancer in this trial.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.8.3-2"></a>

###### Final results at the May 17, 2024 data cutoff: response durability, Kaplan-Meier estimates, progression-free and cystectomy-free survival

> “As of the data cutoff on February 5, 2024, the CR rate in the intention-to-treat (ITT) population at 12-months and any time, was 57% (20/35) [95% confidence interval (CI), 40-73%] and 83% (29/35) (95% CI, 70-95%), respectively.”
> “As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).”
> “Of the patients in a CR at 12 months, 95% of patients (19/20) maintained a CR for another 12 months.”
> “Median DoR has not been reached but exceeds 21 months.”
> “Additionally, the Kaplan-Meier estimates for CR rate at 12 and 24 months were 77.3% (95% CI, 58.1-88.5%) and 69.6% (95% CI, 49.4-83.0%), respectively.”
> “Progression-free survival (PFS) at 24 months is 100% with no patients progressing to muscle invasive cancer or metastatic disease; Cystectomy-free survival (CFS) at 24 months was 80%; for patients in CR, CFS at 24 months was 100%.”

Source: [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)

<a id="topic-3.1.3.8.3-3"></a>

###### Complete response at any time, 12 months, and 24 months in the annual report

> “Final results from the CORE-001 demonstrated that, as of the May 17, 2024 data cutoff, 29 of the 35 (82.9%; 95% CI, 70.4-95.3%) evaluable patients displayed a CR at any time subsequent to completion of induction therapy.”
> “As of the May 17, 2024 data cutoff, 29 of the 35 (82.9%; 95% CI, 70.4-95.3%) patients achieved a CR at any time, with 57.1% (n=20/35, 95% CI, 39.5-73.2%) of patients maintaining a CR at 12 months, and 54.3% (n=19/35, 95% CI, 36.9-70.8%) of patients maintaining a CR at 24 months, indicating that 95.1% of patients in CR at 12 months remain in CR at 24 months.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.3.8.3-4"></a>

###### Correction to the key of the duration-of-response figure

> “In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph.”

Source: [Nature Medicine CORE-001 publisher correction (2024)](https://www.nature.com/articles/s41591-024-03157-6)

<a id="topic-3.1.3.8.3-5"></a>

###### Exploratory urinary minimal residual disease analysis across BOND-003 and CORE-001

> “UroAmp stratified patients treated with Cretostimogene as MRD positive or negative and was associated with durable 12 mo. RFS.”
> “Longitudinal MRD assessment may be able to support the stratification of treatment escalation or de-escalation in future clinical trials.”

Source: [Mokkapati (2025)](https://cgoncology.com/wp-content/uploads/2025/11/A0793_Mokkapati_EAU-2025_BOND-003-and-CORE-001-Convergent_Final-V7-1.pdf)

Additional sources: [Li et al. (2024b)](https://cgoncology.com/wp-content/uploads/2025/11/REQ082_ASCO_2024_Roger-Li_CORE-001_Final_Website.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Treatment-related adverse events in the published final results

> “Adverse events attributed to cretostimogene were low grade, self-limiting and predominantly limited to bladder-related symptoms.”
> “A total of 5 out of 35 patients (14.3%) developed grade 3 treatment-related adverse effects.”
> “There was no evidence of overlapping or synergistic toxicities.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.8.5-2"></a>

###### Treatment-related adverse effects by maximum severity

| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | Total (N = 35), n (%) |
| --- | --- | --- | --- | --- |
| Participants with at least one study drug-related treatment-emergent adverse effect | “9 (25.7)” | “18 (51.4)” | “5 (14.3)” | “32 (91.4)” |
| Bladder spasm | “13 (37.1)” | “4 (11.4)” | “0” | “17 (48.6)” |
| Fatigue | “11 (31.4)” | “2 (5.7)” | “0” | “13 (37.1)” |
| Dysuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Pollakiuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Hematuria | “5 (14.3)” | “1 (2.9)” | “0” | “6 (17.1)” |
| Micturition urgency | “4 (11.4)” | “2 (5.7)” | “0” | “6 (17.1)” |
| Diarrhea | “4 (11.4)” | “0” | “1 (2.9)” | “5 (14.3)” |
| Nocturia | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Hypothyroidism | “1 (2.9)” | “3 (8.6)” | “0” | “4 (11.4)” |
| Urinary tract infection | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Blood alkaline phosphatase increased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Ejection fraction decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Neutrophil count decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Adrenal insufficiency | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Immune-mediated hepatitis | “0” | “0” | “1 (2.9)” | “1 (2.9)” |

Source: [Nature Medicine CORE-001 article Table 2 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/2)

<a id="topic-3.1.3.8.5-3"></a>

###### Attribution of grade 3 or higher events and table inclusion rules

> “The table presents study drug-related adverse effects that occurred in at least 10% or more of all treated patients (n = 35) and all study drug-related grade 3 events.”
> “AEs include all events that occurred or worsened after the first dose of cretostimogene or pembrolizumab.”
> “There were no grade 3–5 cretostimogene drug-related adverse effects.”
> “There were no grade 4–5 pembrolizumab drug-related adverse effects.”

Source: [Nature Medicine CORE-001 article Table 2 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/2)

<a id="topic-3.1.3.8.5-4"></a>

###### Author correction removing attribution of immune-related adverse effects from the abstract

> “In the version of the article initially published, the text”
> “Immune-related adverse effects were exclusively associated with pembrolizumab”
> “and, in the following sentence, also referring to adverse effects,”
> “…all related to pembrolizumab”
> “has been removed from the Abstract.”
> “assessed by the treating physicians”
> “Related adverse effect to pembrolizumab…”

Source: [Nature Medicine CORE-001 author correction (2024)](https://www.nature.com/articles/s41591-024-03137-w)

<a id="topic-3.1.3.8.5-5"></a>

###### Safety summary in the annual report

> “The safety profile was favorable, with no overlapping or synergistic toxicity observed.”
> “Adverse events attributed to cretostimogene were Grade 1 or Grade 2 and self-limited.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.3.8.5-6"></a>

###### Grade 3 events and absence of grade 4 or 5 events in the interim presentation

> “Grade 3 AE included (4 total patients)”
> “Autoimmune hepatitis”
> “Reduced ejection fraction”
> “Neutrophil count decreased”
> “Alkaline phosphatase increased”
> “Adrenal insufficiency”
> “Grade 4 / 5 AE – none observed”

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.3.8.5-7"></a>

###### Adverse event grading and serious adverse event capture in the clinical study protocol

> “Serious adverse events (SAEs) will be captured from Day 1 through 90 days after the last treatment with CG0070 or pembrolizumab or, if the patient initiates new anticancer therapy, through 30 days after the last treatment with CG0070 or pembrolizumab.”
> “All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

CORE-001 was a single-arm, open-label phase 2 trial of 35 participants with no control arm, so the contribution of cretostimogene to the combination cannot be separated from that of pembrolizumab within the trial. The protocol tested a 12-month complete response rate of 19% (H0) against 36% (Ha) at a one-sided alpha of 0.10 with approximately 81% power, and required 30 evaluable participants. The 12-month complete response rate was 57.1% (20 of 35; 95% CI 40.7% to 73.5% in the publication and 39.5% to 73.2% in the annual report). The 24-month complete response rate was 51.4% (18 of 35) in the publication and 54% (19 of 35) at the later May 17, 2024 data cutoff reported by the company. Long-term efficacy and survival follow-up stopped under Protocol Amendment 7, so data beyond 24 months were not collected. Thirty of 35 participants (85.7%) were enrolled in the USA and 5 (14.3%) in Korea; 33 (94.3%) were male. Pembrolizumab dosing changed during the trial from 200 mg every 3 weeks to 400 mg every 6 weeks, and the DDM concentration is described as 5% in the protocol synopsis and registry record and as 0.1% in the protocol administration procedure. An author correction removed the abstract statements that attributed immune-related adverse effects exclusively to pembrolizumab, and added that attribution of adverse effects to pembrolizumab was “assessed by the treating physicians”. Long-term follow-up assessments were based on local review.

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3); [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1); [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf); [Nature Medicine CORE-001 author correction (2024)](https://www.nature.com/articles/s41591-024-03137-w); [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.9-2"></a>

###### Discontinuation of long-term efficacy and survival follow-up under protocol amendment 7

> “Under Protocol Amendment 7, no additional Long-Term Efficacy Follow-Up assessments will be completed, and no additional Long-Term Efficacy Follow-Up data will be collected.”
> “Under Protocol Amendment 7, no additional Survival Follow-Up data will be collected.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.9-3"></a>

###### Additional patient data may differ from data at the cutoff

> “additional patient data related to cretostimogene in combination with pembrolizumab that continues to become available may be inconsistent with the data produced as of the data cutoff, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof”

Source: [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)

<a id="topic-3.1.3.9-4"></a>

###### Single-arm trials appropriate only while no effective therapy is available in FDA guidance

> “If effective therapies become available in BCG-unresponsive NMIBC, a randomized trial may be appropriate.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 BOND-002

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered study purpose

> “To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.1-2"></a>

###### Objective of the interim analysis

> “We evaluated interim results of a phase II trial for intravesical CG0070 in patients with BCG-unresponsive NMIBC who refused cystectomy.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registered study dates and sites

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-06-02” |
| Primary completion (actual) | “2018-08” |
| Study completion (actual) | “2019-02” |
| Number of sites | “This study has 17 locations” |
| Principal investigator | “Gary Steinberg, MD” |

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.2-2"></a>

###### Interim analysis date

> “At interim analysis (April 2017)”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Registered design: open-label, single-arm, phase 2

> “An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG (Bacillus Calmette-Guerin) Therapy and Refused Cystectomy”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.3-2"></a>

###### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.3-3"></a>

###### Company description of the design and population

> “The BOND-002 trial was a Phase 2, open-label, single-arm clinical trial of cretostimogene in patients with high-risk NMIBC after BCG failure.”
> “The trial included a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Inclusion: high-grade NMIBC after prior intravesical therapy including BCG

> “Patients must have pathologically confirmed non-muscle invasive bladder cancer (NMIBC) high grade disease (HG), as defined by the 2004 WHO classification system”
> “Patients must have received at least two or more prior courses of intravesical therapy per recommended schedules. Bacillus Calmette-Guerin (BCG) must have been one of the prior therapies administered.”
> “Patients can have either failed BCG induction therapy within a six-month period or have been successfully treated with BCG, but subsequently found to have recurrence. The first standard course of intravesical BCG therapy must include at least six weekly treatments (allowable range of instillations per course is 4-9). The second course of BCG therapy must include at least two weekly treatments.”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-2"></a>

###### Inclusion: carcinoma in situ, or recurrent Ta or T1 disease

> “Patients have either Cis or Cis with Ta and/or T1 disease at enrollment or in the past. For those patients with only Ta or T1 disease at enrollment AND with no history of Cis, they must have”
> “disease recurrence either must occur within 12 months of the most recent intravesical therapy of any kind, OR”
> “disease recurrence within 18 months of BCG maintenance OR”
> “disease recurrence within 24 months of BCG induction”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-3"></a>

###### Inclusion: cystectomy declined, age, and performance status

> “Radical cystectomy has been declined by the patient in a signed special section of the informed consent, whereby there is a clear explanation by the investigator to the subject that a delay of cystectomy may increase his/her chance of disease progression, the results of which may lead to serious and life threatening consequences.”
> “18 years of age or older”
> “Eastern Cooperative Oncology Group (ECOG) performance status <2.”
> “Absolute lymphocyte count ≥ 800/μL before the first dose of CG0070”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-4"></a>

###### Exclusion criteria

> “Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable”
> “Known infection with HIV, HBV or HCV.”
> “Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted).”
> “History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine) within the last year”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.4-5"></a>

###### Prior therapy of the interim population

> “All patients received at least 2 prior courses of intravesical therapy for CIS, with at least 1 being a course of BCG.”
> “Patients had either failed BCG induction therapy within 6 months or had been successfully treated with BCG with subsequent recurrence.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Registered regimen

> “Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.”
> “oncolytic adenovirus with a E2F promotor and expresses GMCSF”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.5-2"></a>

###### Company description of dose, induction, and maintenance

> “Cretostimogene was administered intravesically at 1x1012 viral particles (VPs) per milliliter to patients who had refused radical cystectomy”
> “Patients received an initial induction course of six weekly administrations.”
> “Patients who achieved a CR at month six received six weekly maintenance doses of cretostimogene using the same concentration.”
> “Patients whose disease did not respond to the first induction course received accelerated maintenance at month three to four, which involved early administration of the maintenance normally provided at six months.”
> “Six weekly follow up doses were then administered at months 12 and 18.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Durable Complete Response at 18 Months as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary endpoint: durable complete response proportion

> “Durable Complete Response Proportion (DCR)”
> “Defined as the proportion of patients who experience a durable complete response lasting 12 months or longer from the initial confirmed complete response date (first CR assessment to be at least 6 months after the first intravesical intervention) and at least 18 months from the date of the first intravesical intervention”
> “18 months time point from the date of the first intravesical intervention”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.6.1-2"></a>

###### Registered secondary endpoints

> “Cystectomy Free Survival”
> “Progression Free Survival”
> “Time to Progression to Muscle Invasive Disease”
> “PD-L1 status of cancer cells and immune cells at tumor site by IHC”
> “Proportions of patients with a complete response of at least 12 months' duration”
> “Proportions of patients with a partial response and/or a complete response of less than 12 months' duration”

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.6.1-3"></a>

###### Endpoint reported in the interim analysis: complete response at 6 months

> “Complete response (CR) at 6 months was defined as absence of disease on cytology, cystoscopy, and random biopsies.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.6.1-4"></a>

###### Regulatory context for durable complete response in single-arm trials

> “attainment of a durable CR may represent clinical benefit by allowing some patients to delay or”
> “forgo radical cystectomy.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “66” |

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants enrolled, by disease group

> “A total of 65 patients were enrolled, which included 46 CIS patients, with or without Ta/T1 disease, and 19 patients with Ta/T1 disease.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Interim efficacy set: participants with 6-month follow-up

> “At interim analysis (April 2017), 45 patients with residual high-grade Ta, T1, or carcinoma-in-situ (CIS) ± Ta/T1 had evaluable 6-month follow-up in this phase II single-arm multicenter trial”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.7.2-2"></a>

###### Safety set: protocol participants and three additional treated patients

> “In addition to the 65 patients enrolled per the trial protocol, the safety results above included three additional patients, two who were dosed with cretostimogene for compassionate, single-use patient INDs and one more determined not to have baseline NMIBC retrospectively.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Tumor stage at entry in the interim population

> “Of 45 patients, there were 24 pure CIS, 8 CIS + Ta, 4 CIS + T1, 6 Ta, 3 T1.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Complete response at 6 months: interim analysis

> “Overall 6-month CR (95% CI) was 47% (32%-62%).”
> “Considering 6-month CR for pathologic subsets, pure CIS was 58% (37%-78%), CIS ± Ta/T1 50% (33%-67%), and pure Ta/T1 33% (8%-70%).”
> “At 6 months, the single patient that progressed to muscle-invasive disease had Ta and T1 tumors at baseline.”
> “No patients with pure T1 had 6-month CR.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.8.3-2"></a>

###### Complete response at any time and duration of response: company report

> “Among the 40 (61.5%) patients achieving a CR at any timepoint, the median DOR had yet to be reached after 18 months, with 21 patients (52.5%) without disease progression at 18 months.”
> “Specifically in the 46 patients with high-risk CIS-containing NMIBC, 30 (65.2%; 95% CI, 49.7-78.2%) patients displayed a CR at any time subsequent to administration of cretostimogene.”
> “Four out of 10 (40.0%) patients who did not achieve CR at three months, and who were subsequently re-dosed with cretostimogene at three months demonstrated CR at six months.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.4.8.3-3"></a>

###### Complete response at 6 and 12 months in CIS-containing disease: company report

> “Among the 46 patients with high-risk CIS-containing NMIBC, 30 (65%; 95% CI: 50-78%) patients displayed a CR at any time subsequent to administration of cretostimogene.”
> “44% and 28% of patients demonstrating a CR at six months and 12 months, respectively”

Source: [CG Oncology prospectus (2024)](https://www.sec.gov/Archives/edgar/data/1991792/000119312524015534/d551455d424b4.htm)

Additional sources: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf); [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Treatment-related adverse events at 6 months: interim analysis

> “Treatment-related adverse events (AEs) at 6 months were most commonly urinary bladder spasms (36%), hematuria (28%), dysuria (25%), and urgency (22%).”
> “Immunologic treatment-related AEs included flu-like symptoms (12%) and fatigue (6%).”
> “Grade III treatment-related AEs included dysuria (3%) and hypotension (1.5%). There were no Grade IV/V treatment-related AEs.”

Source: [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/)

<a id="topic-3.1.4.8.5-2"></a>

###### Treatment-related and serious adverse events: company report

> “Cretostimogene was generally well-tolerated and most TRAEs were limited to Grade 1 to 2, only two Grade 3 TRAEs involving dysuria and hypotension (both of which were resolved), and no Grade 4 or 5 TRAEs.”
> “Furthermore, eight serious adverse events (SAEs) were reported but were determined not related to cretostimogene.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: limitations of BOND-002

- Design: BOND-002 was a phase 2, open-label, single-arm study with no comparator arm.
- Population: the 10-K describes the enrolled population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. Eligibility allowed participants whose second BCG course had as few as two weekly treatments, and 19 of the 65 enrolled participants had Ta/T1 disease alongside 46 with CIS, so the population differs from the BCG-unresponsive population of BOND-003.
- Endpoint reporting: the registered primary endpoint is durable complete response lasting 12 months or longer and assessed at 18 months. The only peer-reviewed report is an interim analysis of 45 participants that reported complete response at 6 months (47%). The final figures (40 of 65 participants, 61.5%, with complete response at any time; 30 of 46 participants, 65.2%, with CIS-containing disease) come from company filings, and no peer-reviewed report of the registered primary endpoint was identified.
- Enrollment counts differ by source: the registry lists 66 participants enrolled, and the 10-K reports 65 enrolled per protocol, with 3 additional treated participants in the safety set.
- Regimen: maintenance in BOND-002 was six weekly instillations at months 6, 12, and 18, a schedule that differs from the one used in BOND-003.
- No results posted on ClinicalTrials.gov were identified.

Source: [ClinicalTrials.gov NCT02365818](https://clinicaltrials.gov/study/NCT02365818); [Packiam et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28755959/); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.5"></a>

#### 3.1.5 BOND

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Registered study purpose

> “It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy.”
> “It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population.”
> “This opportunity allows a study on the CG0070's beneficial effects, if any, on the standard of care for carcinoma in situ non muscle invasive bladder cancer patients after they failed BCG therapy.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registered study dates and sites

| Field | Quoted record |
| --- | --- |
| Study start | “2014-03” |
| Primary completion (actual) | “2016-06” |
| Number of sites | “This study has 7 locations” |
| Study chair | “Alex W Yeung, MBBS” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Registered design: integrated phase 2/3 randomized controlled trial

> “An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG”
> “It is therefore, desirable to formulate a protocol to encompass the specialty of this oncolytic vaccine and the unique intravesical delivery to prove the efficacy by a randomized controlled study.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.3-2"></a>

###### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Inclusion: high-grade disease with carcinoma in situ after BCG

> “Patients must be considered high risk, with pathologically confirmed high grade disease (HG) WHO 2004”
> “Patients must have pathologically-proven unresectable, primary, secondary or concurrent carcinoma in situ disease, defined by having either Ta and/or T1 with CIS, or CIS”
> “Patients must have received at least two or more prior courses of intravesical therapy. BCG must have been one of the prior therapies administered. Patients can have either failed BCG induction therapy within a six month period or have been successfully treated with BCG, but subsequently found to have recurrence.”
> “Residual disease at accrual”
> “Patient to provide a tumor specimen for determination of RB pathway status”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.4-2"></a>

###### Inclusion: cystectomy indicated, age, and performance status

> “Patient need to sign a specific informed consent acknowledging that a delay of cystectomy may lead to an increase chance of progression and/or metastasis with serious or sometimes fatal consequences.”
> “18 years of age or older”
> “Eastern Cooperative Oncology Group (ECOG) performance status <2.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.4-3"></a>

###### Exclusion criteria

> “Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable”
> “No bladder cancer residual disease, such as patients that are rendered disease free by TURBT”
> “History of partial cystectomy in the setting of bladder cancer primary tumor.”
> “Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis)”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Experimental arm: CG0070 after DDM pretreatment

> “Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes”
> “CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.5-2"></a>

###### Control arm: investigator choice of intravesical chemotherapy or interferon

> “Quadruple Choice as interventions”
> “Mitomycin C”
> “Interferon”
> “Valrubicin”
> “Gemcitabine”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Complete Response as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registered primary endpoint, phase 2 part: complete response at 9 months

> “Complete Response Proportion (CR)”
> “'CR' Proportion is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after first intravesical treatment and then assessed again at 9 month.”
> “9 months (Phase II)”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.6.1-2"></a>

###### Registered primary endpoint, phase 3 part: durable complete response at 15 months

> “Durable Complete Response Proportion (DCR)”
> “DCR proportion of DCR lasting 12 months or longer will be conducted after a follow up period of 15 months for each patient. The first complete response assessment will be at 3 month.”
> “15 months (Phase III)”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.6.1-3"></a>

###### Registered secondary endpoints

> “Progression rate to muscle invasive disease”
> “Complete Response Survival”
> “The number and percentage of patients experiencing one or more adverse events will be summarized by relationship to study drug, and severity.”
> “Cystectomy Free Survival”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.6.1-4"></a>

###### Regulatory context for durable complete response in single-arm trials

> “attainment of a durable CR may represent clinical benefit by allowing some patients to delay or”
> “forgo radical cystectomy.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.7.1-2"></a>

###### Planned between-arm comparisons

> “The Complete Response Survival time to events of patients who have achieved a complete response at the 3 month assessment will be compared with a log rank test.”
> “The Cystectomy Free Survival time to events of patients will be compared with a log rank test.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Study termination

| Field | Quoted record |
| --- | --- |
| Reason for stopping | “Change in study design” |
| Study completion (actual) | “2016-06” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: limitations of BOND

- BOND was registered as an integrated phase 2/3, open-label, randomized study of CG0070 against investigator choice of mitomycin C, interferon, valrubicin, or gemcitabine in participants with CIS-containing disease after BCG.
- The registry lists the study as terminated for a “Change in study design” with 22 participants enrolled, from March 2014 to June 2016.
- No results posted on ClinicalTrials.gov and no publication or company report of its efficacy or safety results were identified, so the study contributes no efficacy or safety data to this report.
- Eligibility allowed participants who had been “successfully treated with BCG, but subsequently found to have recurrence”, so the registered population differs from the BCG-unresponsive population of BOND-003.

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.6"></a>

#### 3.1.6 V-0046

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Registered study purpose

> “The main purpose of this research study is to evaluate the safety and dosing of CG0070.”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.1-2"></a>

###### Purpose stated in the phase 1 publication

> “We assessed the safety, pharmacokinetics and anticancer activity of intravesical CG0070, a cancer selective, replication competent adenovirus, for the treatment of nonmuscle invasive bladder cancer.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Registered study dates, sponsor, and sites

| Field | Quoted record |
| --- | --- |
| Study start | “2005-04” |
| Primary completion (estimated) | “2008-10” |
| Study completion (estimated) | “2010-09” |
| Number of sites | “This study has 10 locations” |

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Registered design: phase 1 dose escalation

> “A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure”
> “Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.3-2"></a>

###### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.3-3"></a>

###### Single-dose and multi-dose schedules

> “This trial evaluated the safety and feasibility of single and multiple doses of CG0070. Multi-dose regimens were tested at two schedules: every 4 weeks or weekly.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Inclusion criteria

> “High grade non-muscle invasive bladder cancer (stages Ta, T1 and/or CIS - carcinoma in situ). High grade being defined as G2 or G3 disease.”
> “Failure of at least one prior treatment with BCG, defined as evidence of TCC on cystoscopic exam and biopsy or cystoscopic exam and urine cytology at least 6 weeks from last BCG treatment”
> “ECOG performance status 0-1”
> “Adequate bone marrow, renal, liver and coagulation function”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.4-2"></a>

###### Exclusion criteria

> “Use of anticoagulants such as coumadin or heparin”
> “Active systemic autoimmune disease or chronic immunodeficiency”
> “Prior gene therapy”
> “Uncontrolled cystitis, bladder pain, bladder spasms, urinary incontinence, or reduced bladder volume”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Dose levels and schedules administered

> “A total of 35 patients received single or multiple (every 28 days × 3 or weekly × 6) intravesical infusions of CG0070 at 1 of 4 dose levels (1 × 10(12), 3 × 10(12), 1 × 10(13) or 3 × 10(13) viral particles).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-3.1.6.5-2"></a>

###### Pretreatment with dodecyl-maltoside

> “All patients receive dodecyl-maltoside, a mild detergent, prior to CG0070 to enhance penetration of the mucosal layer.”

Source: [Senzer et al. (2006)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(06)00324-8)

<a id="topic-3.1.6.5-3"></a>

###### Registered intervention

> “Intravesical administration of CG0070 (in suspension) directly into the bladder”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Maximum Tolerated Dose as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Registered primary endpoint: maximum tolerated or maximum feasible dose

> “Maximum-tolerated or maximum feasible dose in single and multidose regimens of CG0070 by intravesical administration”
> “Assessment of the amount of CG0070 in the urine and blood over time by PCR”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.6.1-2"></a>

###### Primary goals stated at study start: safety and maximum tolerated dose

> “The primary goals for this study of intravesical (IVE) CG0070 in patients with existing TCC after BCG failure is the evaluation of safety and the identification of a maximum tolerated dose.”
> “Assessment of response rate and progression free survival is also planned.”

Source: [Senzer et al. (2006)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(06)00324-8)

<a id="topic-3.1.6.6.1-3"></a>

###### Response and pharmacokinetic assessments

> “Response to treatment was based on cystoscopic assessment and biopsy or urine cytology.”
> “Urine and plasma CG0070, and granulocyte-monocyte colony-stimulating factor were measured in all patients.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “75” |

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.7.1-2"></a>

###### Participants treated

> “A total of 35 patients received single or multiple (every 28 days × 3 or weekly × 6) intravesical infusions of CG0070”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Retinoblastoma phosphorylation subset

> “A subset of 18 patients was assessed for retinoblastoma phosphorylation status.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Participants treated by schedule and dose range

> “35 patients (pts) were treated with CG0070 at doses ranging from 1012 to 3 x 1013 viral particles (vp) in the single dose schedule, and from 1012 to 1013 vp per dose in the weekly x 6 and every 4 week x 3 cohorts.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="topic-3.1.6.8.1-2"></a>

###### Interim accrual by schedule

> “Thirteen patients have been treated with intravesical single dose CG0070 up to 3×1013 viral particles [vp]; 9 pts have been treated with a multi-dose schedule at the first dose level (1×1012 vp) at one of two schedules: 6 administrations given weekly or 3 administrations given once every 4 weeks.”

Source: [Nemunaitis et al. (2008)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)40090-0)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Tumor stage of enrolled participants

> “N = 35 NMIBC CIS-containing or Ta/T1”

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

Additional sources: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Complete response rate and duration: phase 1 publication

> “The complete response rate and median duration of the complete response across cohorts was 48.6% and 10.4 months, respectively.”
> “In the multidose cohorts the complete response rate for the combined groups (every 28 days and weekly × 6) was 63.6% (14 of 22 patients).”
> “In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-3.1.6.8.3-2"></a>

###### Complete response rate: congress report

> “A complete response rate (RR) of 46% was observed for all pts.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="topic-3.1.6.8.3-3"></a>

###### Complete response at 3 months by schedule: company presentation

| Schedule | Complete response at 3 months |
| --- | --- |
| Single dose | “3/13 (23%)” |
| Every 28 days | “6/13 (46%)” |
| Weekly × 6 | “7/9 (78%)” |
| Multi-dose (every 28 days and weekly × 6) | “13/22 (59%)” |
| Total | “16/35 (46%)” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.6.8.3-4"></a>

###### Complete response at 3 months by dose: company presentation

| Dose | Complete response at 3 months |
| --- | --- |
| 1 × 10^12 viral particles | “8/13 (62%)” |
| 3 × 10^12 viral particles | “4/9 (44%)” |
| 1 × 10^13 viral particles | “4/10 (40%)” |
| 3 × 10^13 viral particles | “0/3 (0%)” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.6.8.3-5"></a>

###### Duration of complete response: company presentation

> “Median Duration: 8.4 months, with responses ongoing at 17.0 months”

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.6.8.3-6"></a>

###### Urine GM-CSF and viral genome measurements

> “High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.”
> “Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Adverse events and maximum tolerated dose: phase 1 publication

> “Grade 1-2 bladder toxicities were the most common adverse events observed.”
> “A maximum tolerated dose was not reached.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-3.1.6.8.5-2"></a>

###### Dose-limiting toxicity and flu-like illness: congress report

> “No SAEs and only one dose limiting toxicity was reported, gr 3 lymphopenia, at a dose of 1012 vp on the every 4 week schedule.”
> “Transient, local bladder related toxicities were the most common adverse events reported including dysuria, hematuria, urgency, bladder spasm, nocturia, and pain.”
> “Flu-like illness was also observed in 10–20% of patients including fever, chills, fatigue, and myalgias.”
> “The maximum tolerated dose was not reached in the single or multi-dose cohorts.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="topic-3.1.6.8.5-3"></a>

###### Adverse events at the first multi-dose level: interim congress report

> “In the multi-dose schedules at dose level 1, common related, adverse events include bladder discomfort, hematuria, dysuria, fatigue, tissue excretion, urgency, and frequency (all grade 1/2).”
> “There has been 1 episode of grade 3 transient lymphopenia in a patient receiving multidose CG0070 after the 3rd dose and no grade 4 toxicities noted.”

Source: [Nemunaitis et al. (2008)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)40090-0)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary: limitations of V-0046

- Design: V-0046 was a phase 1, open-label, non-randomized dose-escalation study in 35 participants, with cohorts of three to six participants at each dose and schedule, so efficacy estimates rest on small subgroups (for example, 9 participants on the weekly × 6 schedule).
- Population: eligibility required failure of at least one prior BCG treatment and allowed G2 disease, which differs from the BCG-unresponsive definition used in BOND-003.
- Reported results differ by source: the 2012 publication reports a complete response rate of 48.6% with a median duration of 10.4 months, a 2010 congress report gives 46%, and a 2023 company presentation gives 16 of 35 participants (46%) at 3 months with a median duration of 8.4 months. The multi-dose complete response rate is 63.6% (14 of 22) in the publication and 13 of 22 (59%) in the presentation.
- The association between retinoblastoma phosphorylation and response (81.8%, 9 of 11) comes from an exploratory, retrospective assessment of a subset of 18 participants.
- The registry record lists an estimated primary completion in October 2008 and an estimated enrollment of 75 participants, against 35 participants treated.
- Only the abstract of the 2012 publication is openly available.

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655); [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/); [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7); [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
